| 264.18 3.25 (1.25%) | 04-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 315.63  |
1-year : | 324.61 |
| Resists | First : | 270.23 |
Second : | 277.92 |
| Pivot price | 268.18 |
|||
| Supports | First : | 257.79 |
Second : | 214.48 |
| MAs | MA(5) : | 268.45 |
MA(20) : | 267.65 |
| MA(100) : | 266.93 |
MA(250) : | 262.19 |
|
| MACD | MACD : | -1.1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 37.2 |
D(3) : | 52.8 |
| RSI | RSI(14): 44.3 |
|||
| 52-week | High : | 292.2 | Low : | 207.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ LH ] has closed above bottom band by 27.3%. Bollinger Bands are 11% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 266.01 - 267.5 | 267.5 - 268.86 |
| Low: | 253.87 - 255.82 | 255.82 - 257.6 |
| Close: | 261.33 - 264.18 | 264.18 - 266.79 |
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Tue, 14 Apr 2026
Labcorp Holdings Inc. $LH Shares Sold by AMI Asset Management Corp - MarketBeat
Mon, 13 Apr 2026
Labcorp Holdings Inc. $LH Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Sun, 12 Apr 2026
Earnings Preview: What to Expect From Labcorp Holdings' Report - FinancialContent
Sun, 12 Apr 2026
Labcorp Holdings Inc SEC Filings - Stock Titan
Fri, 10 Apr 2026
A Look At Labcorp Holdings (LH) Valuation After Positive Analyst Ratings And Expanded Testing Initiatives - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 82 (M) |
| Shares Float | 82 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 100.3 (%) |
| Shares Short | 2,990 (K) |
| Shares Short P.Month | 3,020 (K) |
| EPS | 10.46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 104.86 |
| Profit Margin | 6.2 % |
| Operating Margin | 10.5 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 10.5 % |
| Qtrly Rev. Growth | 5.5 % |
| Gross Profit (p.s.) | 48.66 |
| Sales Per Share | 169.29 |
| EBITDA (p.s.) | 26.57 |
| Qtrly Earnings Growth | 15.6 % |
| Operating Cash Flow | 1,640 (M) |
| Levered Free Cash Flow | 967 (M) |
| PE Ratio | 25.25 |
| PEG Ratio | 0 |
| Price to Book value | 2.51 |
| Price to Sales | 1.56 |
| Price to Cash Flow | 13.27 |
| Dividend | 0.72 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|